I want to give read­ers a quick up­date on the most im­por­tant part of our busi­ness mod­el — pre­mi­um sub­scrip­tions. We have some cru­cial fi­nan­cial goals we hope to achieve by the end of the year, and the team here in Lawrence is ready to ship some swag to kick off this lim­it­ed De­cem­ber pro­mo­tion.

We of­fer two pre­mi­um plans — En­ter­prise for com­pa­nies ($1,000/year, un­lim­it­ed peo­ple), and In­sid­er for in­di­vid­u­als ($200/year). This month of De­cem­ber will be the last chance to en­roll at the orig­i­nal rates — which have re­mained flat since we launched them in 2017.

Both plans un­lock ac­cess to our en­tire pre­mi­um con­tent li­brary like 100 top VCs in bio­phar­ma, Re­al World End­points: the brave new world com­ing in build­ing fran­chise ther­a­pies, and the top 20 pre­clin­i­cal biotech deals, and much more. You get ac­cess to tools like down­load­ing ar­ti­cles to PDF, our VIP sup­port team, and most of all, you’re di­rect­ly fund­ing the fu­ture de­vel­op­ment of End­points. These plans have been the rea­son we’ve been able to make new ed­i­to­r­i­al hires, with more to come. And we’re adding new ben­e­fits next year: paid sub­scribers will have ex­clu­sive ac­cess to watch our an­nu­al event at JP Mor­gan live at no ad­di­tion­al cost.

• In­di­vid­u­als — sign-up for In­sid­er. All of the ben­e­fits above plus the op­tion to dis­able all ad­ver­tis­ing across web and email, and dis­count­ed tick­ets to End­points events. $200/year, end­ing soon.
  
• Com­pa­nies — sign-up for En­ter­prise. Cov­ers every­one at your or­ga­ni­za­tion for $1,000/year. In­cludes a reprint li­cense to re­pur­pose and dis­trib­ute End­points con­tent in­ter­nal­ly. All em­ploy­ees will al­so be­gin to see a new “Your com­pa­ny sup­ports in­de­pen­dent jour­nal­ism” ban­ner in their dai­ly email re­ports.

By up­grad­ing, you’re di­rect­ly sup­port­ing in­de­pen­dent bio­phar­ma re­port­ing, and we’re look­ing for ways big and small to help pro­mote that among our read­ers. And that’s where the swag comes in.

The next 100 In­sid­er ac­counts to sign-up will re­ceive these vinyl stick­ers — 4 in a se­ries — that our stu­dio cre­at­ed.

And the next new 25 En­ter­prise sub­scribers will get stick­ers plus one of these amaz­ing­ly com­fort­able hood­ies. (Our sup­port team will reach out to get your pre­ferred size!)

Fi­nal­ly, the stu­dio cre­at­ed 100 lim­it­ed edi­tion framed cer­tifi­cates in hon­or of the very first batch of com­pa­nies who signed up for the En­ter­prise plan back when we launched it in the sum­mer of 2017. You can see a copy of what they look like at the top of this post.

These sub­scrip­tion plans helped End­points scale up to where we are to­day: serv­ing 400,000 unique read­ers per month on the web and near­ly 70,000 bio­phar­ma pros dai­ly by email, sup­port­ed by a glob­al­ly dis­trib­uted work­force, 15-strong and grow­ing, head­quar­tered in Lawrence, Kansas.

And we have big plans for 2020 — new cov­er­age ar­eas, prod­ucts, and deep­er re­port­ing on the peo­ple and trends that shape the bio­phar­ma world. The best way to help us get there is up­grad­ing to In­sid­er or En­ter­prise.

If you de­pend on End­points, it’s a sure bet we de­pend on you too. So please join us now be­fore De­cem­ber 31 while our orig­i­nal In­sid­er and En­ter­prise rates re­main. You can al­ways con­tact our help­ful sup­port team at help@end­pointsnews.com or by vis­it­ing your Read­er Pro­file.

Dupixent, the blockbuster anti-inflammatory drug from Sanofi and Regeneron, has cleared a high-stakes Phase III study in chronic obstructive pulmonary disease, the companies announced Thursday morning.

If they hold up in a second, identical trial, the data pave the way for Dupixent to become the first biologic to treat patients whose COPD remains uncontrolled despite being on maximal standard-of-care inhaled therapy — the patient population studied in the pivotal program. The companies had spotlighted this as a key readout as they look to expand the Dupixent franchise and explore its full potential.

Incyte touted an accelerated approval for its PD-1 retifanlimab in a rare skin cancer on Wednesday, roughly a year and a half after the drug suffered a rejection in squamous cell carcinoma of the anal canal (SCAC).

Retifanlimab, marketed as Zynyz, was approved for metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), a fast-growing skin cancer typically characterized by a single, painless nodule. It’s roughly 40 times rarer than melanoma, according to the nonprofit Skin Cancer Foundation — but incidence is growing, particularly among older adults, Incyte said in its announcement.

Novartis is calling off a UK-based trial for Leqvio in the primary prevention of cardiovascular events in patients with high cholesterol, the company confirmed on Wednesday.

The Swiss pharma giant made the decision after “careful evaluation,” a spokesperson told Endpoints News via email. The trial, dubbed ORION-17, was planned in partnership with England’s National Health Service (NHS) and was part of the company’s strategy to establish Leqvio as a standard of care in cardiovascular disease management.